CBE ID
0585
1.5 Project
Endorsement Status
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
1.6 Measure Description
This measure identifies the percentage of patients with Rheumatoid Arthritis who received hydroxychloroquine during the measurement year and had a fundoscopic examination during the measurement year or in the year prior to the measurement year
Measure Specs
General Information
1.7 Measure Type
1.3 Electronic Clinical Quality Measure (eCQM)
No
1.8 Level of Analysis
1.9 Care Setting
1.20 Types of Data Sources
Numerator
1.14 Numerator
Patients in the denominator who have undergone a retinal eye exam or who have an E&M visit with an eye care professional during the measurement year
Denominator
1.15 Denominator
Patients with a diagnosis of rheumatoid arthritis who are at high risk for hydroxychloroquine ocular complications and were prescribed at least a 292-day supply of hydroxychloroquine during the measurement year, excluding those with a prior history of blindness
Exclusions
Exclusions
Blindness
Measure Record
Most Recent Endorsement Activity
Measure Retired and Endorsement Removed EENT Endorsement Maintenance Project 2014
Initial Endorsement
Last Updated
Removal Date
Point of Contact
Steward Organization
Resolution Health, Inc.
Steward POC email
Importance
Care Gaps
Feasibility
Scientific Acceptability
Risk Adjustment
Risk Adjustment
Use & Usability
Use
6.1.2 Current or Planned Use(s)
6.1.3 Current or Planned Use(s)
Public Comments